SAN FRANCISCO, Dec. 21, 2017 (GLOBE NEWSWIRE) -- Zacks Small-Cap Research's John Vandermosten discussed the potential for this immunotherapy firm's RNAi compounds in oncology.

Included in this article is: RXi Pharmaceuticals Corp. (NASDAQ:RXII)

In a Dec. 7 Zacks Small-Cap article, John Vandermosten explained how RXi Pharmaceuticals Corp.'s self-delivering RNA interference (sd-rxRNA) technology may be used in conjunction with adoptive cell transfer (ACT) cancer therapies to "enhance their effectiveness and durability."

These ACT processes include endogenous T-cell therapy, T-cell receptor-transduced T cells and, currently most researched, tumor infiltrating lymphocyte (TIL) therapy and chimeric antigen receptor T-cell (CAR-T) therapy. The most common disease targets for TIL therapy are melanoma and solid cancers whereas for CAR-T therapy they are leukemia, lymphoma and other blood cancers.

Vandermosten noted that "ACT is especially conducive to combination therapy with interference RNA (RNAi) as it can augment ACT's efficacy, impact expression of immune cell proteins and maintain immune cells in a stem-like state, which enhances their propagation and longevity."

Continue reading this article: 'Exciting' Collaborations Possible for Biotech's 'Flexible' Platform 

About Streetwise Reports – The Life Sciences Report

Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.

DISCLOSURES:

The following company mentioned in this article is a billboard sponsor of Streetwise Reports: RXi Pharmaceuticals Corp. Streetwise Reports does not accept stock in exchange for its services. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. 

Please see the end of the article for the complete disclosures: : 'Exciting' Collaborations Possible for Biotech's 'Flexible' Platform